IP Library › Granted Patent US 12,194,086
Granted Patent B2
US 12,194,086 · App. 16/755,257 · Granted Jan 14, 2025

Mayaro virus consensus antigens, DNA antibody constructs for use against Mayaro virus, and combinations thereof

Inventors: David B. Weiner (Merion, PA); Kar Muthumani (Cherry Hill, NJ); Sagar Kudchodkar (Philadelphia, PA)
Assignee: The Wistar Institute of Anatomy and Biology
A61K39/12C07K16/1081C12N15/86A61K2039/505C12N2770/36122
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,194,086
App. No.
16/755,257
Granted
Jan 14, 2025
Kind
B2
Abstract

Disclosed herein is a composition comprising a nucleic acid sequence encoding a Mayaro Virus antigen that elicits an immune response in a mammal. Also disclosed herein is a nucleic acid sequence encoding an anti-Mayaro Virus antibody, a fragment thereof, a variant thereof. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a Mayaro virus infection in a subject using said composition and method of generation.

Claims (20)

1. A composition

composition comprising a nucleic acid molecule comprising a nucleotide sequence encoding a Mayaro virus (MAYV) antigen

wherein

the MAYV antigen comprises MAYV-E1, MAYV-E2, MAYV-E3, and MAYV-6K, wherein the MAYV antigen comprises SEQ ID NO:116.

2. The composition of claim 1 , wherein

the nucleic acid molecule encoding MAYV antigen comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO:117, a nucleotide sequence that is 90% identical or greater to SEQ ID NO:117, a fragment of SEQ ID NO:117 and a fragment of a nucleotide sequence that is 90% identical or greater to SEQ ID NO:117.

3. The composition of claim 1 , wherein

a) the composition further comprises nucleic acid sequences that encode one or more proteins selected from the group consisting of: IL-12, IL-15 and IL-28; or

b) the MAYV antigen is linked to an IgE leader sequence.

4. A method of inducing an immune response comprising administering the composition of claim 1 to an individual in an amount effective to induce an immune response in said individual.

5. A nucleic acid molecule comprising SEQ ID NO: 117 or a nucleotide sequence that is 90% identical or greater to SEQ ID NO:117.

6. The nucleic acid molecule of claim 5 , wherein

a) the nucleic acid molecule further comprises a nucleotide sequence encoding a cleavage domain;

b) the nucleic acid molecule comprises an expression vector; or

c) the nucleotide sequence encodes a leader sequence.

7. A composition comprising the nucleic acid molecule of claim 5 .

8. The composition of claim 7 , further comprising a pharmaceutically acceptable excipient.

9. A protein comprising SEQ ID NO:116.

10. A method of inducing an immune response comprising administering the nucleic acid molecule of claim 5 or a composition thereof to an individual in an amount effective to induce an immune response in said individual.

11. The method of claim 10 , wherein the immune response is an anti-MAYV immune response.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2022
From: WEINER, DAVID; MUTHUMANI, KAR; KUDCHODKAR, SAGAR
To: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
Reel/Frame 060935/0444 →
Continuity (4)
Provisional Application 62571487 · Oct 12, 2017
Provisional Application 62571498 · Oct 12, 2017
Provisional Application 62571514 · Oct 12, 2017
Related Publication 20200237895A1 · Jul 30, 2020
References Cited (49)
US 20140170186A1 · Nabel · 2014 [cited by examiner]
US 20160215282A1 · Lin · 2016 [cited by applicant]
US 20170073377A1 · Nabel · 2017 [cited by applicant]
WO 2017165460 · 2017 [cited by applicant]
Choi et al., PLoS Neglected Tropical Diseases, 2019, 13(2):e0007042, 21 pages. (Year: 2019). [cited by examiner]
Auguste et al., Emerging Infectious Diseases, Oct. 2015, 21(10):1742-1750. (Year: 2015). [cited by examiner]
GenBank Accession No. ALI88617.1, Oct. 14, 2015. (Year: 2015). [cited by examiner]
Terzian et al., Am. J. Trop. Med. Hyg., 2015, Epub 2014, 92(2):401-404. (Year: 2014). [cited by examiner]
GenBank Accession No. AJA30086.1 (2014) (Year: 2014). [cited by examiner]
GenBank Accession No. KM400598.1 (2014) (Year: 2014). [cited by examiner]
Abad-Franch F et al. “Mayaro virus infection in amazonia: a multimodel inference approach to risk factor assessment”. PLoS Negl Trop Dis. 2012;6(10):e1846. doi: 839 10.1371/journal.pntd.0001846. [cited by applicant]
Aitken TH et al., “Mayaro virus isolated from a Trinidadian mosquito”, [cited by applicant]
Auguste AJ, et al., “Evolutionary and Ecological Characterization of Mayaro Virus Strains Isolated during an Outbreak”, Venezuela, 2010. Emerg Infect Dis. 2015;21(10):1742-50. doi: 10.3201/eid2110.141660. [cited by applicant]
Duperret et al., 2018, “Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT”, Mol Ther 26(2):435-445. [cited by applicant]
El-Bacha et al., 2004, “Mayaro virus infection alters glucose metabolism in cultured cells through activation of the enzyme 6-phosphofructo 1-kinase”, Mol Cell Biochem 266(1-2):191-8. [cited by applicant]
Fisher et al., 2017, “Adipose tissue: a new target for electroporation-enhanced DNA vaccines”, Gene Ther 24(12):757-67. [cited by applicant]
Forshey BM, Guevara C, Laguna-Torres VA, Cespedes M, Vargas J, Gianella A, et al. Arboviral etiologies of acute febrile illnesses in Western South America, 2000-2007. PLoS Negl Trop Dis. 2010;4(8):e787. doi: 10.1371/jou… [cited by applicant]
Fox et al., 2015, “Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress”, Cell 163(5):1095-107. [cited by applicant]
Fox et al., 2016, “Immune-Mediated Protection and Pathogenesis of Chikungunya Virus”, J Immunol 197(11):4210-18. [cited by applicant]
Genbank Accession No. KM400598, “Mayaro virus strain FSB1131 structural polyprotein gene, partial cds,” 2014. [cited by applicant]
Gorchakov et al., 2012, “Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein”, J Virol 86(11):6084-96. [cited by applicant]
Haist et al., 2017, “Inflammatory monocytes mediate control of acute alphavirus infection in mice”, PLoS Pathog. 13(12):e1006748. [cited by applicant]
Hassing RJ et al., “Imported Mayaro virus infection in the Netherlands”, J Infect. 2010;61(4):343-5. doi: 10.1016/j.jinf.2010.06.009. [cited by applicant]
Herrero LJ, Nelson M, Srikiatkhachorn A, Gu R, Anantapreecha S, Fingerle-Rowson G, et al. Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis. Proc Natl Acad… [cited by applicant]
Herrero LJ, Sheng KC, Jian P, Taylor A, Her Z, Herring BL, et al. Macrophage migration inhibitory factor receptor CD74 mediates alphavirus-induced arthritis and myositis in murine models of alphavirus infection. Arthrit… [cited by applicant]
Lavergne A, de Thoisy B, Lacoste V, Pascalis H, Pouliquen JF, Mercier V, et al. Mayaro virus: complete nucleotide sequence and phylogenetic relationships with other alphaviruses. Virus Res. 2006;117(2):283-90. [cited by applicant]
Lednicky et al., 2016, “Mayaro Virus in Child with Acute Febrile Illness”, Emerg Infect Dis 22(11):2000-2. [cited by applicant]
Lin F, Shen X, Kichaev G, Mendoza JM, Yang M, Armendi P, et al. Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum Gene Ther Methods. 2012;23(3):1… [cited by applicant]
Llagonne-Barets et al., “A case of Mayaro virus infection imported from French Guiana”. J Clin Virol. 2016;77:66-68. doi: 10.1016/j.jcv.2016.02.013. [cited by applicant]
Long KC et al., “Experimental transmission of Mayaro virus by Aedes aegypti”. Am J Trop Med Hyg. 2011;85(4):750-7. doi: 10.4269/ajtmh.2011.11-0359. [cited by applicant]
Mackay et al., 2016, “Mayaro virus: a forest virus primed for a trip to the city?”, Microbes Infect 18(12):724-34. [cited by applicant]
Mallilankaraman et al., 2011, “A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates”, PLoS Negl Trop Dis 5(1):e298. [cited by applicant]
Muthumani et al., 2015, “A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates”, Sci Transl. Med. 7(301):301ra132. [cited by applicant]
Muthumani et al., 2016, “In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine”, NPJ Vaccines 1:1602. [cited by applicant]
Muthumani et al., 2016, “Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus”, J Infect Dis 214(3):369-78. [cited by applicant]
Robinson et al., “Inactivated Mayaro vaccine produced in human diploid cell cultures”, Mil Med. 1976;141(3):163-166. [cited by applicant]
Rodriguez-Morales et al., 2017, “Mayaro, Oropouche and Venezuelan Equine Encephalitis viruses: Following in the footsteps of Zika?”, Travel Med Infect Dis 15:72-73. [cited by applicant]
Rulli NE, Melton J, Wilmes A, Ewart G, Mahalingam S. The molecular and cellular aspects of arthritis due to alphavirus infections: lesson learned from Ross River virus. Ann N Y Acad Sci. 2007;1102:96-108. [cited by applicant]
Santiago et al., “Long-Term Arthralgia after Mayaro Virus Infection Correlates with Sustained Pro-inflammatory Cytokine Response”, PLoS Negl Trop Dis 9(10):e0004104 (2015). [cited by applicant]
Smith GC et al., “Laboratory studies of a Brazilian strain of Aedes albopictus as a potential vector of Mayaro and Oropouche viruses”. J Am Mosq Control Assoc. 1991;7(1). [cited by applicant]
Snyder JE, Kulcsar KA, Schultz KL, Riley CP, Neary JT, Marr S, et al. Functional characterization of the alphavirus TF protein. J Virol. 2013;87(15):8511-23. doi: 10.1128/JVI.00449-13. [cited by applicant]
Suhrbier A, Jaffar-Bandjee MC, Gasque P. Arthritogenic alphaviruses—an overview. Nat Rev Rheumatol. 2012;8(7):420-9. [cited by applicant]
Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, et al. Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine—Preliminary Report. N Engl J Med. 2017. doi: 10.1056/NEJMoa1708120. [cited by applicant]
Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for c… [cited by applicant]
Tsetsarkin KA, McGee CE, Volk SM, Vanlandingham DL, Weaver SC, Higgs S. Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to [cited by applicant]
Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. 2007;3(12):e201. doi: 10.1371/journal.ppat.0030201. [cited by applicant]
UniProtKB Accession No. A0A0A7RBR8, “Structural polyprotein, Mayaro virus,” 2015. [cited by applicant]
Wang et al., 2011, “Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response”, J Virol 85(17):9249-9252. [cited by applicant]
Weise WJ et al., “A novel live-attenuated vaccine candidate for mayaro Fever.” PLoS Negl Trop Dis. 2014;8(8):e2969. [cited by applicant]